Hua Medicine (2552) announced that on November 28, 2025, it granted share options to three executive Directors and 71 employees under the share option scheme adopted on August 26, 2018 and effective September 14, 2018. The total number of share options granted is 20,000,000, each entitling the holder to subscribe for one new share with a nominal value of US$0.001.

The exercise price is set at HK$3.38 per share, and the options have a 10-year validity period. The vesting schedule provides for 30% of the options to vest on May 1, 2027, 30% on May 1, 2028, and the remaining 40% on May 1, 2029, subject to the achievement of performance targets for the financial years ending December 31, 2026, 2027, and 2028. The revenue targets for those years are RMB900 million, RMB1,350 million, and RMB1,800 million, respectively; portions of the options may lapse if the relevant performance thresholds are not met.

Among the grantees, the executive Directors received a total of 4,800,000 options, and 15,200,000 were granted to employees. The share option scheme aims to incentivize participants for their contributions to corporate milestones. Following this grant, the number of shares available for future grant under the scheme mandate is 15,107,033.